PubMed Health⌕ Search

Biomedical subjects

D P Bonner

Publications and source records attributed to D P Bonner.

62 records · Page 4Linked to original sources
PubMed1975

Comparative chemotherapeutic activity of amphotericin B and amphotericine B methy ester.

The comparative efficacy of amphotericin B and amphotericin B methyl ester (AME) against experimental histoplasmosis, blastomycosis, cryptococcosis, and candidosis in mice was assessed by determining the effect of daily intraperitoneal therapy on 21-day survival and persistence of organisms in internal organs. AME, like amphotericin B, was effective against each of the experimental infections, but the efficacy was lower than the parent compound. For Histoplasma and Blastomyces infections the mean effective dose (ED(50)) of amphotericin B was 0.3 mg/kg, whereas the corresponding values for AME, respectively, were 2.4 and 2.8 mg/kg. For Cryptococcus infection the ED(50) for amphotericin B was 0.2 mg/kg compared with 2.0 mg/kg for AME. The ED(50) of amphotericin B for Candida infection was lower than 0.05 mg/kg and the value of AME was between 0.5 to 0.05 mg/kg. The colony counts from internal organs of the surviving animals after the therapeutic regimens were compatible with the data on survival.

Amphotericin B↗
PubMed1975

Stability studies with amphotericin B and amphotericin B methyl ester.

In solid form, amphotericin B and amphotericin B methyl ester free base exhibit similar stability. Acid salts of the methyl ester derivative stored under identical conditions are less stable. In solution, amphotericin B is generally more stable than its methy ester salts. However, when pH is adjusted to 6.0 and storage temperature held at 5 degrees C the methyl ester salts reflect the stability exhibited by the parent compound, amphotericin B.

Amphotericin B↗
PubMed1975

Studies on the absorption, distribution and excretion of radioactivity after intravenous and intraperitoneal administration of 14C-methyl ester of amphotericin B.

Distribution and balance studies with carbon-14-labeled amphotericin B methyl ester (AME) were carried out in mice. The radioactive AME was administered by either the intraperitoneal (i.p.) or intravenous (i.v.) route. In the organ distribution study, the percent radioactivity accumulating in the lung of i.v. treated mice at 1 hour after administration was about 150 times greater than that observed when the intrapertinoneal route was used. No accumulation of radioactivity with time was detected in the kidneys of either the i.v. or i.p. treated mice. After 4 days, about 51% of the total radioactivity was excreted into the urine and feces of mice after i.v. administration, but only about 15% of the total radioactivity was excreted in the case of mice receiving radioactive AME by the i.p. route. In the identification of the substances excreted in the urine, thin-layer chromatography (TLC), radioactivity, and bioautographic evidence suggest that there was no detectable de-esterification of AME to the parent compound in mice treated either intraperitoneally or intravenously with AME.

Amphotericin B↗
PubMed1975

Stimulatory effect of amphotericin B methyl ester on the grwoth of L-M and Vero cells.

The chemically modified polyene macrolide antibiotic, amphotericin B methyl ester (AME), exhibited a concentration-dependent growth stimulatory effect on established lines of mouse (L-M) and monkey (Vero) cells. Stimulation was indicated by increases in growth rate, and in the enhanced synthesis of DNA and RNA. In contrast, the parental antibiotic amphotericin B and the desoxycholate complex of amphotericin B, FungizoneR, did not elicit a similar proliferative response in L-M or Vero cells. AME was not growth-promoting toward low passage strains of mouse (PMK 6) and monkey cells (MGK 8).

Amphotericin B↗
PubMed1975

Toxicity of amphotericin B and its methyl ester toward normal and tumor cell lines.

The toxicity of amphotericin B, amphotericin B methyl ester (AME), and Fungizone toward three "normal" and three tumor-derived human and mouse cell lines was evaluated in monolayer culture. AME was less toxic than amphotericin B and Fungizone to all cell lines, but the sensitivity of the normal and tumor lines was different. The human (HEL-8 and WISH) and mouse (L-M) cells derived from normal tissue were more resistant to AME than the tumor-derived human (KB and HeLa) and mouse (RAG) cell as indicated by: (a) increased 24-hr survival, (b) increased 72-hr viability, and (c) growth rates at higher AME concentrations. In contrast, no pattern of differential sensitivity was observed with amphotericin B and Fungizone.

Amphotericin B↗
PubMedDate not supplied

Discovery and development of the monobactams.

A novel procedure designed to detect naturally occurring beta-lactam-containing molecules led to isolation of the monobactams - structurally unique, bacterially produced, monocyclic beta-lactam antibiotics. Although none of these monobactams exhibited impressive antimicrobial activity, side-chain variation - as with the penicillins and cephalosporins - resulted in potently active compounds. Aztreonam was chosen from hundreds of compounds for extended laboratory studies. In addition to a unique chemical structure, aztreonam has biologic properties that are unique in comparison with those of the classical penicillins and cephalosporins. Aztreonam is relatively inactive against gram-positive bacteria and anaerobes but is extremely effective against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. The drug is highly resistant to enzymatic hydrolysis by beta-lactamases, particularly those known to be mediated by R plasmids, and is a poor inducer of chromosomal beta-lactamases. In the majority of drug combinations tested, aztreonam exhibits additive or synergistic activity. In a series of animal-model infections, the drug showed a high degree of efficacy that was consistent with findings in studies in vitro. In a hamster model for Clostridium difficile-induced pseudomembranous colitis, aztreonam did not induce any significant changes.

Animals↗